Journal of Antimicrobial Chemotherapy, Vol 39, 71-77, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
K Ohtsuka, M Watanabe, Y Orikasa, S Inouye, K Uchida, H Yamaguchi, S Kondo and T Takeuchi
The in-vivo antifungal activity of benanomicin A administered intravenously
or subcutaneously was compared with that of amphotericin B and fluconazole
using animal models of systemic infections with Candida albicans,
Aspergillus fumigatus and Cryptococcus neoformans. The efficacy of
benanomicin A in C. albicans infection was more pronounced when
administered in multiple doses than in a single dose. This was also true of
fluconazole, but not of amphotericin B, which showed no difference between
single and multiple dosings. Benanomcin A eradicated C. albicans cells from
the kidneys of infected mice in a manner comparable to that of amphotericin
B, but more effectively than fluconazole. The histopathological findings
obtained from the kidneys of the C. albicans-infected mice confirmed the
therapeutic efficacy of benanomicin A. The subcutaneous ED50 values of
benanomicin A were 1.30 mg/kg/day (C. albicans) and 19.0 mg/kg/day (A.
fumigatus) which were intermediate between those of amphotericin B and
fluconazole in the two models. The subcutaneous ED50 value of benanomicin A
for C. neoformans was 21.5 mg/kg/day, which was higher than that of
amphotericin B.
JOURNAL ARTICLE
The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole
Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A.N.B. Ellepola and L.P. Samaranayake Oral Candidal Infections and Antimycotics Critical Reviews in Oral Biology & Medicine, January 1, 2000; 11(2): 172 - 198. [Abstract] [Full Text] [PDF]
|
|